Roswell Park Cancer Institute Purchases Six Ion Torrent Sequencers
CARLSBAD, Calif., Feb. 21, 2013
CARLSBAD, Calif., Feb. 21, 2013 /PRNewswire/ -- Life Technologies Corporation
(NASDAQ: LIFE) today announced that the new Center for Personalized Medicine
(CPM) at Roswell Park Cancer Institute (RPCI) has purchased four Ion Proton™
sequencers and two Ion Personal Genome Machine™ (PGM™) sequencers.
Founded in 1898, Roswell Park Cancer Institute was one of the first cancer
centers in the country to be named a National Cancer Institute-designated
comprehensive cancer center and is a member of the prestigious National
Comprehensive Cancer Network.
"A key part of our mission at the Center involves research into new therapies,
new diagnostic tools and better ways of predicting patient outcomes," said
Carl Morrison, MD, DVM, Executive Director of the Center for Personalized
Medicine. "The sequencers will be central to this work, quicklygenerating
vast amounts of genomic data that will help us to understand the mechanisms of
how cancer develops and spreads."
"The combination of the Ion Proton™ sequencer and the Ion PGM™ sequencer will
give the researchers from Roswell Park Cancer Institute a simple workflow from
discovery to validation," said Life Technologies President and Chief Operating
Officer Mark Stevenson. "Over 1,000 organizations have adopted Ion Torrent
technology in the past two years, giving our company more than 60 percent of
the desktop sequencer market and reflecting the huge demand for the speed,
simplicity and affordability of Ion Torrent technology."
All products referenced are for research use only and not for use in
About Life Technologies
Life Technologies Corporation(NASDAQ:LIFE) is a global biotechnology company
with customers in more than 160 countries using its innovative solutions to
solve some of today's most difficult scientific challenges. Quality and
innovation are accessible to every lab with its reliable and easy-to-use
solutions spanning the biological spectrum, with more than 50,000 products for
agricultural biotechnology, translational research, molecular medicine and
diagnostics, stem cell-based therapies, forensics, food safety and animal
health. Its systems, reagents and consumables represent some of the most cited
brands in scientific research including: Ion Torrent™, Applied
Biosystems®,Invitrogen™, Gibco®, Ambion®, Molecular Probes® and Novex®.Life
Technologiesemploys approximately 10,400 people and upholds its ongoing
commitment to innovation with more than 4,000 patents and exclusive licenses.
LIFE had sales of$3.8 billionin 2012. Visit us at our
Life Technologies' Safe Harbor Statement
This press release includes forward-looking statements about Life
Technologies' anticipated results that involve risks and uncertainties. Some
of the information contained in this press release, including, but not limited
to, statements as to industry trends and Life Technologies' plans, objectives,
expectations and strategy for its business, contains forward-looking
statements that are subject to risks and uncertainties that could cause actual
results or events to differ materially from those expressed or implied by such
forward-looking statements. Any statements that are not statements of
historical fact are forward-looking statements. When used, the words
"believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and
the like, and/or future tense or conditional constructions ("will," "may,"
"could," "should," etc.), or similar expressions, identify certain of these
forward-looking statements. Important factors which could cause actual results
to differ materially from those in the forward-looking statements are detailed
in filings made by Life Technologies with the Securities and Exchange
Commission. Life Technologies undertakes no obligation to update or revise any
such forward-looking statements to reflect subsequent events or circumstances.
Life Technologies Contact
SOURCE Life Technologies Corporation
Press spacebar to pause and continue. Press esc to stop.